

ASX Announcement

6 June 2025

Capital Consolidation Complete

Sydney, Australia – 6 June 2025: Pancreatic cancer treatment device company **OncoSil Medical Limited** (ASX:OSL) (“OncoSil” or “the Company”) advises that the consolidation of the Company’s issued capital on a 1 for 400 basis, as set out in the Notice of Extraordinary General Meeting dated 30 April 2025 and approved by shareholders at the Meeting on 29 May 2025, is now complete.

The Company’s post consolidation capital structure is set out below:

ASX code	Description	Number on issue	
Quoted securities		Pre-consolidation	Post consolidation
OSL	ORDINARY FULLY PAID	5,689,087,238	14,224,271
OSLO	OPTION EXPIRING 30-APR-2027 EX \$12.00*	1,701,126,544	4,253,161
OSLOB	OPTION EXPIRING 30-JUN-2025 EX \$3.60*	1,914,424,362	4,786,231
OSLOC	OPTION EXPIRING 20-DEC-2027 EX \$6.00*	856,000,000	2,140,009
Unquoted securities			
OSLAB	PERFORMANCE RIGHTS	99,075,676	247,692
OSLAM	PERFORMANCE RIGHTS EXPIRING 25-OCT-2026	9,659,800	24,156
OSLAN	OPTION EXPIRING 25-OCT-2027 EX \$48.00*	4,182,482	10,457
OSLAR	OPTION EXPIRING 29-NOV-2028 EX \$12.00*	49,000,000	122,500

** Option exercise prices shown post consolidation*

New holding statements are being dispatched to security holders advising them of their securities held on a post consolidation basis. Normal trading of securities on a post consolidation basis will commence on Friday 13 June 2025.

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Nathan Jong Company Secretary E: Nathan.Jong@acclime.com T: +61 3 9864 4810	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699
--	--	---

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>